Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

588
Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
588
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

687
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
687
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

558
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
558
Cardiomyopathy I: Introduction and Classification01:25

Cardiomyopathy I: Introduction and Classification

722
Cardiomyopathy, or CMP, is a group of diseases affecting the myocardial structure, impairing its ability to pump blood effectively. This condition can lead to arrhythmias, heart failure, or sudden cardiac death.Cardiomyopathies are classified into primary and secondary categories:Primary Cardiomyopathy refers to conditions involving only the heart muscle that are often idiopathic (of unknown cause) or genetic. They primarily affect the myocardium without the involvement of other systemic...
722
Coronary Artery Disease III: Clinical Manifestations01:30

Coronary Artery Disease III: Clinical Manifestations

497
Coronary Artery Disease (CAD) is a primary health risk worldwide, leading to significant morbidity and mortality. The condition arises from the buildup of atherosclerotic plaques within the coronary arteries, resulting in diminished blood supply to the heart muscle.The clinical manifestations of CAD vary widely, from asymptomatic stages to severe, life-threatening conditions. Understanding these manifestations is crucial for early diagnosis and effective management.Angina Pectoris: The Warning...
497
Imbalances in Cardiac Output01:26

Imbalances in Cardiac Output

3.3K
The heart's primary function is to pump blood throughout the body, maintaining a balance between blood sent out (cardiac output) and blood returning (venous return). If this balance is disrupted, it can result in congestive heart failure (CHF), a severe condition where the heart becomes an inefficient pump, leading to inadequate blood circulation.
CHF can occur due to the failure of either side of the heart. Left-side failure leads to pulmonary congestion—the right side continues to send...
3.3K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

[Antibiotic prophylaxis for infective endocarditis: current approaches].

Kardiologiia·2021
Same author

[Anaemia and iron deficiency in chronic heart failure patients].

Kardiologiia·2019
Same author

[The case of repeated syncopes in recurrent pulmonary embolism].

Kardiologiia·2018
Same author

[Infective endocarditis in the elderly: The current view of the problem].

Terapevticheskii arkhiv·2017
Same author

[The Development of Pulmonary Damage When Receiving Amiodarone].

Kardiologiia·2017
Same author

[True polycythemia: current views of pathogenesis, diagnostics and treatment].

Klinicheskaia meditsina·2012

Related Experiment Video

Updated: Mar 6, 2026

Investigating the Pathogenesis of MYH7 Mutation Gly823Glu in Familial Hypertrophic Cardiomyopathy using a Mouse Model
03:45

Investigating the Pathogenesis of MYH7 Mutation Gly823Glu in Familial Hypertrophic Cardiomyopathy using a Mouse Model

Published on: August 8, 2022

4.3K

[Sudden Cardiac Death in Patients With Hypertrophic Cardiomyopathy].

N Vatutin1, G G Taradin1, M S Maron1

  • 11Donetsk national medical university named after M. Gorky, Donetsk, Ukraine; 2Tuft University School of Medicine, Hypertrophic Cardiomyopathy Center, Tufts Medical Center, Boston, Massachusetts, USA.

Kardiologiia
|March 16, 2017
PubMed
Summary
This summary is machine-generated.

Sudden cardiac death (SCD) in hypertrophic cardiomyopathy (HCM) affects young individuals and athletes. Risk stratification and implantable cardioverter-defibrillators (ICD) are key to preventing SCD in HCM patients.

More Related Videos

Isolation and Functional Characterization of Human Ventricular Cardiomyocytes from Fresh Surgical Samples
14:39

Isolation and Functional Characterization of Human Ventricular Cardiomyocytes from Fresh Surgical Samples

Published on: April 21, 2014

18.0K
Scanning Electron Microscopy of Macerated Tissue to Visualize the Extracellular Matrix
10:21

Scanning Electron Microscopy of Macerated Tissue to Visualize the Extracellular Matrix

Published on: June 14, 2016

10.7K

Related Experiment Videos

Last Updated: Mar 6, 2026

Investigating the Pathogenesis of MYH7 Mutation Gly823Glu in Familial Hypertrophic Cardiomyopathy using a Mouse Model
03:45

Investigating the Pathogenesis of MYH7 Mutation Gly823Glu in Familial Hypertrophic Cardiomyopathy using a Mouse Model

Published on: August 8, 2022

4.3K
Isolation and Functional Characterization of Human Ventricular Cardiomyocytes from Fresh Surgical Samples
14:39

Isolation and Functional Characterization of Human Ventricular Cardiomyocytes from Fresh Surgical Samples

Published on: April 21, 2014

18.0K
Scanning Electron Microscopy of Macerated Tissue to Visualize the Extracellular Matrix
10:21

Scanning Electron Microscopy of Macerated Tissue to Visualize the Extracellular Matrix

Published on: June 14, 2016

10.7K

Area of Science:

  • Cardiology
  • Sports Medicine
  • Genetics

Background:

  • Hypertrophic cardiomyopathy (HCM) is a primary cause of sudden cardiac death (SCD), particularly in young individuals and athletes.
  • Understanding the prevalence and risk factors for SCD in HCM is crucial for effective prevention strategies.

Purpose of the Study:

  • To review the current literature on sudden cardiac death (SCD) in hypertrophic cardiomyopathy (HCM).
  • To discuss the prevalence, risk factors, and pathophysiological mechanisms of SCD in HCM.
  • To evaluate risk stratification methods and the role of implantable cardioverter-defibrillators (ICD) in SCD prevention.

Main Methods:

  • Comprehensive literature review of studies on sudden cardiac death (SCD) in hypertrophic cardiomyopathy (HCM).
  • Analysis of prevalence, demographic factors (age, sex), and exercise-induced risk.
  • Evaluation of arrhythmogenic substrates and ventricular tachyarrhythmia.
  • Review of risk stratification criteria and clinical trials on implantable cardioverter-defibrillators (ICD).

Main Results:

  • Sudden cardiac death (SCD) prevalence varies in young individuals and athletes with hypertrophic cardiomyopathy (HCM).
  • Factors like age, sex, and myocardial response to exercise influence SCD risk.
  • Implantable cardioverter-defibrillators (ICD) show efficacy in primary and secondary SCD prevention in HCM patients, though complication rates must be considered.

Conclusions:

  • Accurate risk stratification is essential for identifying individuals with hypertrophic cardiomyopathy (HCM) at high risk of sudden cardiac death (SCD).
  • Implantable cardioverter-defibrillators (ICD) represent a vital therapeutic option for SCD prevention in selected HCM patients.
  • Further research is needed to optimize ICD implantation criteria and minimize complications.